News & Resources
Capital Markets Day Presentation and Video 2025
Capital Markets Day Presentation and Video 03 November 2025 IXICO plc (AIM: IXI) – London, UK.
Advancing AD Trials: Integrating Plasma Biomarkers and Imaging for Precision Enrolment
The development of blood-based biomarkers (BBMs) for early detection of Alzheimer’s disease (AD) pathology is transformative for research and drug development. Historically, diagnosis relied on symptomatic presentation with costly confirmatory imaging. Today, the field is shifting toward a biologically defined framework for earlier detection and trial stratification.
Trading update for the year ended 30 September 2025
16 October 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced a trading update, pre-audit, for its financial year ended 30 September 2025 (“FY25”).
New blood based biomarker contract win and contract extension worth a total of £1.2 million
15 October 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has signed a new commercial contract to assist in the validation of a diagnostic blood test, reaffirming the Company’s expertise in this area. IXICO has also entered into a contract extension on an existing Alzheimer’s Disease (AD) clinical trial. The combined value of the new contract and contract extension is c. £1.2 million.
A Quick Guide to Imaging Analysis & Operations Essentials in Parkinson’s Disease Clinical Research
As clinical research in Parkinson’s Disease (PD) continues to evolve, neuroimaging has become a cornerstone in trial design, patient selection, and therapeutic evaluation. Across the industry, sponsors and imaging partners are adopting increasingly sophisticated imaging strategies to enhance data quality, regulatory compliance, and scientific insight.
IXICO wins "CRO Provider of the Year 2025" at the Precision Medicine Awards!
We’re proud to announce that IXICO has been named CRO Provider of the Year at the Precision Medicine Awards 2025, hosted by Oxford Global. This award celebrates our commitment to advancing precision in neuroscience through cutting-edge neuroimaging and AI-powered analytics.
1-8 of 177 results